Morten Valberg

• Choi, Hye Jung; Leblanc, Marissa Erin; Moger, Tron Anders; Valberg, Morten; Page, Christian Magnus & Aamodt, Geir [Show all 7 contributors for this article] (2023). Geographical variation in cardiovascular disease mortality in Norway: The role of life course socioeconomic position and parental health. Health and Place. ISSN 1353-8292. 83. doi: 10.1016/j.healthplace.2023.103095. Full text in Research Archive Show summary

  Despite substantial geographical variation in cardiovascular (CVD) mortality within countries, little is known about whether this variation can be explained by individuals' life course socioeconomic position (SEP) or differences in family history of premature CVD deaths. Cox proportional hazards models were used to investigate the association between the county of residence at ages 50–59 and CVD death in Norwegians born between 1940 and 1959 and survived to at least age 60, using national data. Individual life course SEP and family history of premature CVD death reduced the geographical variation in CVD mortality across Norwegian counties, but some significant differences remained. Furthermore, CVD risk varied by residents' migration histories between two counties with distinct CVD and socioeconomic profiles.

• Brathovde, Mari; Moger, Tron Anders; Aalen, Odd O.; Grotmol, Tom; Veierød, Marit Bragelien & Valberg, Morten (2023). A lean additive frailty model: With an application to clustering of melanoma in Norwegian families. Statistics in Medicine. ISSN 0277-6715. p. 1–29. doi: 10.1002/sim.9856. Full text in Research Archive
• Methi, Fredrik; Gran, Jon Michael; Valberg, Morten; Kinge, Jonas Minet; Telle, Kjetil & Magnusson, Karin (2023). Third dose mRNA vaccination against SARS-CoV-2 reduces medical complaints seen in primary care: a matched cohort study. BMC Medicine. ISSN 1741-7015. 21, p. 1–15. doi: 10.1186/s12916-023-02870-2. Full text in Research Archive Show summary

  Background SARS-CoV-2 mRNA vaccination has been associated with both side effects and a reduction in COVID-related complaints due to the decrease in COVID-19 incidence. We aimed to investigate if individuals who received three doses of SARS-CoV-2 mRNA vaccines had a lower incidence of (a) medical complaints and (b) COVID-19-related medical complaints, both as seen in primary care, when compared to individuals who received two doses. Methods We conducted a daily longitudinal exact one-to-one matching study based on a set of covariates. We obtained a matched sample of 315,650 individuals aged 18–70 years who received the 3rd dose at 20–30 weeks after the 2nd dose and an equally large control group who did not. Outcome variables were diagnostic codes as reported by general practitioners or emergency wards, both alone and in combination with diagnostic codes of confirmed COVID-19. For each outcome, we estimated cumulative incidence functions with hospitalization and death as competing events. Results We found that the number of medical complaints was lower in individuals aged 18–44 years who received three doses compared to those who received two doses. The differences in estimates per 100,000 vaccinated were as follows: fatigue 458 less (95% confidence interval: 355–539), musculoskeletal pain 171 less (48–292), cough 118 less (65–173), heart palpitations 57 less (22–98), shortness of breath 118 less (81–149), and brain fog 31 less (8–55). We also found a lower number of COVID-19-related medical complaints: per 100,000 individuals aged 18–44 years vaccinated with three doses, there were 102 (76–125) fewer individuals with fatigue, 32 (18–45) fewer with musculoskeletal pain, 30 (14–45) fewer with cough, and 36 (22–48) fewer with shortness of breath. There were no or fewer differences in heart palpitations (8 (1–16)) or brain fog (0 (− 1–8)). We observed similar results, though more uncertain, for individuals aged 45–70 years, both for medical complaints and for medical complaints that were COVID-19 related. Conclusions Our findings suggest that a 3rd dose of SARS-CoV-2 mRNA vaccine administered 20–30 weeks after the 2nd dose may reduce the incidence of medical complaints. It may also reduce the COVID-19-related burden on primary healthcare services.

• Ahimbisibwe, Ashley; Valberg, Morten; Green, Adele C.; Ghiasvand, Reza; Rüegg, Corina Silvia & Rimal, Raju [Show all 10 contributors for this article] (2023). Nevus Count, Pigmentary Characteristics, and Melanoma-specific Mortality among Norwegian Women with Melanoma >1.0 mm Thick. Acta Dermato-Venereologica. ISSN 0001-5555. 103. doi: 10.2340/actadv.v103.4403. Full text in Research Archive
• Choi, Hye Jung; Leblanc, Marissa Erin; Moger, Tron Anders; Valberg, Morten; Aamodt, Geir & Page, Christian Magnus [Show all 8 contributors for this article] (2022). Stroke survival and the impact of geographic proximity to family members: A population-based cohort study. Social Science and Medicine. ISSN 0277-9536. 309. doi: 10.1016/j.socscimed.2022.115252. Full text in Research Archive Show summary

  Introduction Familial support may be important for post-stroke survival. Objective To determine if geographical proximity between stroke survivors and their family members, i.e having a spouse/partner or distance to a nearest first-degree relative (parents, siblings, and offspring), as a proxy for familial support, is related to survivor mortality. Methods This study included all stroke survivors (n=128,227) hospitalised in Norway from 1994 to 2009, who were 30 years or older at the time of the stroke (born before 1965). National registries and censuses were used to calculate the distance to the nearest first-degree relative in the hospitalisation year. Cox proportional hazards models estimated hazard ratios (HRs) of all-cause mortality from 1994 to 2014 (mean 6.4 years follow-up), adjusting for sociodemographic and clinical covariates. Results Living up to 30 km from the nearest first-degree relative was associated with a higher mortality (HR 1.04, 95% CI: 1.03 to 1.06) than those living in the same household or neighbourhood as their nearest first-degree relatives. The association was more pronounced (1.13, 1.08 to 1.19 for ≤30 km; 1.25, 1.16 to 1.35 for >30 km) in survivors hospitalised at age ≤65 years, compared to older survivors. Among familial care predictors, having a spouse/partner was the most prominent predictor of reduced mortality (0.80, 0.78 to 0.82) in stroke survivors. Conclusion Living close to first-degree relatives was weakly associated with better survival in stroke patients while having a spouse/partner exhibited a stronger association. Both associations were larger for survivors hospitalised at age ≤65 years. Our findings thus suggest that the impact of familial support on survival after stroke may differ by familial support condition and patient's age at a stroke hospitalisation.

• Myhrvold, Ståle; BROUWER, ESPEN FREMMO; Andresen, Tor Kristian Molstad; Rydevik, Karin; Amundsen, Madeleine & Grün, Wolfram [Show all 10 contributors for this article] (2022). Nonoperative or Surgical Treatment of Acute Achilles' Tendon Rupture. New England Journal of Medicine. ISSN 0028-4793. 386(15), p. 1409–1420. doi: 10.1056/NEJMoa2108447. Full text in Research Archive
• Skulberg, Arne Kristian; Tylleskär, Ida; Valberg, Morten; Braarud, Anne-Cathrine ; Dale, Jostein & Heyerdahl, Fridtjof [Show all 10 contributors for this article] (2022). Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial. Addiction. ISSN 0965-2140. 117(6), p. 1658–1667. doi: 10.1111/add.15806.
• Gjefsen, Elisabeth; Bråten, Lars Christian Haugli; Goll, Guro Løvik; Wigemyr, Monica; Bolstad, Nils & Valberg, Morten [Show all 27 contributors for this article] (2020). The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial. BMC Musculoskeletal Disorders. ISSN 1471-2474. 21:698, p. 1–14. doi: 10.1186/s12891-020-03720-5. Full text in Research Archive
• Skulberg, Arne Kristian; Tylleskär, Ida; Næss, Anne-Cathrine Braarud; Dale, Jostein; Heyerdahl, Fridtjof & Mellesmo, Sindre [Show all 8 contributors for this article] (2020). NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open. ISSN 2044-6055. 10:e041556(11), p. 1–8. doi: 10.1136/bmjopen-2020-041556. Full text in Research Archive Show summary

  Abstract Introduction Intranasal naloxone is widely used to treat opioid overdoses. The advantage of nasal administration compared to injection lies in its suitability for administration by lay people as it is needless. Approved formulations of nasal naloxone with bioavailability of approximately 50% have only undergone trials in healthy volunteers, while off-label nasal sprays with low bioavailability have been studied in patients. Randomised clinical trials are needed to investigate efficacy and safety of approved intranasal naloxone in patients suffering overdose. This study investigates whether the administration of 1.4 mg naloxone in 0.1 millilitres per dose is non- inferior to 0.8 mg intramuscular injection in patients treated for opioid overdose. Methods and analysis Sponsor is the Norwegian University of Science and Technology. The study has been developed in collaboration with user representatives. The primary endpoint is the restoration of spontaneous respiration ≥10 breaths/minute based on a sample of 200 opioid overdose cases. Double-dummy design ensures blinding, which will be maintained until the database is locked. Ethics and dissemination The study was approved by the Norwegian Medicines Agency and Regional Ethics Committees (REC: 2016/2000). It adheres to the Good Clinical Practice guidelines as set out by The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Informed consent will be sought through a differentiated model. This allows for deferred consent after inclusion for patients who have regained the ability to consent. Patients who are unable to consent prior to discharge by emergency services are given written information and can withdraw at a later date in line with user recommendations. Metadata will be published in the NTNU Open repository. De-identified individual participant data will be made available to recipients conditional of data processor agreement being entered. Trial registrations: EudraCT number: 2016-004072-22 and Clinicaltrials.gov NCT03518021

• Stensrud, Mats Julius; Aalen, John; Aalen, Odd O. & Valberg, Morten (2019). Limitations of hazard ratios in clinical trials. European Heart Journal. ISSN 0195-668X. 40(17), p. 1378–1383. doi: 10.1093/eurheartj/ehy770.
• Mohn, Cathrine Helene; Halvorsen, Jon Anders; Salvesen, Hege Blix; Lagerløv, Per; Nafstad, Per & Valberg, Morten (2018). Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. JAMA Network Open. ISSN 2574-3805. doi: 10.1001/jamanetworkopen.2018.4145.
• Mohn, Cathrine Helene; Blix, Hege Salvesen; Halvorsen, Jon Anders; Nafstad, Per; Valberg, Morten & Lagerløv, Per (2018). Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. JAMA Network Open. ISSN 2574-3805. 1(7). doi: 10.1001/jamanetworkopen.2018.4145. Full text in Research Archive
• Bugge, Anders; Lund, May-Brith; Valberg, Morten; Brustugun, Odd Terje; Solberg, Steinar & Kongerud, Johny (2018). Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 53(1), p. 221–227. doi: 10.1093/ejcts/ezx274.
• Valberg, Morten; Stensrud, Mats Julius & Aalen, Odd O. (2018). The surprising implications of familial association in disease risk. BMC Public Health. ISSN 1471-2458. 18. doi: 10.1186/s12889-018-5033-5.
• Stensrud, Mats Julius & Valberg, Morten (2017). Inequality in genetic cancer risk suggests bad genes rather than bad luck. Nature Communications. ISSN 2041-1723. 8(1165). doi: 10.1038/s41467-017-01284-y. Full text in Research Archive
• Stensrud, Mats Julius; Aalen, Odd O.; Valberg, Morten & Røysland, Kjetil (2017). Exploring selection bias by causal frailty models: The magnitude matters. Epidemiology. ISSN 1044-3983. 28(3), p. 379–386. doi: 10.1097/EDE.0000000000000621.
• Stensrud, Mats Julius; Strohmaier, Susanne; Valberg, Morten & Aalen, Odd O. (2017). Can chance cause cancer? A causal consideration. European Journal of Cancer. ISSN 0959-8049. 75, p. 83–85. doi: 10.1016/j.ejca.2016.12.022.
• Rancoita, Paola M. V.; Valberg, Morten; Demicheli, Romano; Biganzoli, Elia & di Serio, Clelia (2017). Tumor dormancy and frailty models: A novel approach. Biometrics. ISSN 0006-341X. 73(1), p. 260–270. doi: 10.1111/biom.12559.
• Valberg, Morten; Grotmol, Tom; Tretli, Steinar; Veierød, Marit Bragelien; Moger, Tron Anders & Devesa, Susan S. [Show all 7 contributors for this article] (2016). Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? European Journal of Epidemiology (EJE). ISSN 0393-2990. 20(6), p. 511–520. doi: 10.1007/s10654-016-0185-z.
• Aalen, Odd O.; Valberg, Morten; Grotmol, Tom & Tretli, Steinar (2015). Understanding variation in disease risk: the elusive concept of frailty. International Journal of Epidemiology. ISSN 0300-5771. 44(4), p. 1408–1421. doi: 10.1093/ije/dyu192.
• Valberg, Morten; Grotmol, Tom; Tretli, Steinar; Veierød, Marit Bragelien; Moger, Tron Anders & Aalen, Odd O. (2014). A hierarchical frailty model for familial testicular germ-cell tumors. American Journal of Epidemiology. ISSN 0002-9262. 179(4), p. 499–506. doi: 10.1093/aje/kwt267.
• Valberg, Morten; Grotmol, Tom; Tretli, Steinar; Veierød, Marit Bragelien; Devesa, Susan & Aalen, Odd O. (2012). Frailty modeling of age-incidence curves of osteosarcoma and Ewing sarcoma among individuals younger than 40 years. Statistics in Medicine. ISSN 0277-6715. 31(28), p. 3731–3747. doi: 10.1002/sim.5441.

View all works in Cristin

• Eick, Frode; Vallersnes, Odd Martin; Fjeld, Heidi; Sørbye, Ingvil Krarup; Valberg, Morten & Dahl, Cecilie (2023). Perinatal mortality among pregnant undocumented migrants in Norway 1999-2020: a register-based population study.
• Valberg, Morten; Gran, Jon Michael; Rueegg, Corina Silvia & Leblanc, Marissa Erin (2022). Letter to the editor regarding “Covid-19 transmission in fitness centers in Norway - a randomized trial”. BMC Public Health. ISSN 1471-2458. 22(1). doi: 10.1186/s12889-022-14800-7.
• Hagemo, Jostein Skjalg; Skulberg, Arne Kristian; Rehn, Marius; Valberg, Morten; Pesonen, Maiju & Heimdal, Hans Julius [Show all 7 contributors for this article] (2022). Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial. PLOS ONE. ISSN 1932-6203. 17(5). doi: 10.1371/journal.pone.0268822. Full text in Research Archive
• Stensrud, Mats Julius; Valberg, Morten & Aalen, Odd O. (2017). Can collider bias explain paradoxical associations? Epidemiology. ISSN 1044-3983. 28(4), p. e39–e40. doi: 10.1097/EDE.0000000000000653.
• Aalen, Odd O.; Valberg, Morten; Grotmol, Tom & Tretli, Steinar (2015). Authors' response: Understanding variation in disease risk. International Journal of Epidemiology. ISSN 0300-5771. 44(4), p. 1426–1428. doi: 10.1093/ije/dyv047.

View all works in Cristin